Data Demonstrating Efficacy of Periowave(TM) Photodisinfection Therapy for the Treatment of Gum Disease Presented at 12th Congress of the European Society of Photobiology



    - Presentation by Professor Michael Wilson highlights success of Ondine's
    clinical trials -

    VANCOUVER, Sept. 19 /CNW/ - Ondine Biopharma Corporation (TSX: OBP;
AIM: OBP), a medical technology company, announces that Professor Michael
Wilson presented data demonstrating the efficacy of photodisinfection therapy
for the treatment of gum disease at the 12th Congress of the European Society
of Photobiology on September 4th, 2007 in Bath, UK. In his presentation to the
European scientific community titled "Light-activated antimicrobial agents for
the treatment of periodontitis" Professor Wilson discussed the efficacy of the
photodisinfection by highlighting his substantial pre-clinical research
spanning 20 years and Ondine's positive clinical results utilizing its
Periowave Photodisinfection System.
    Michael Wilson (GRSC, MSc, PhD, DSc, FRCPath) is a Professor of
Microbiology at the Eastman Dental Institute at University College London
(UCL) and Honorary Principal Bacteriologist at the Eastman Dental Hospital. He
is also Editor of the journal, Biofilms, and is a world renowned pioneer in
the development of photodisinfection technologies. Professor Wilson has
published more than 250 original research papers, over 200 scientific research
abstracts relating to antibiotic resistance, biofilms, bacterial virulence
factors, and the development of new antimicrobial strategies and co-authored
four books.
    "It is extremely exciting that a company like Ondine is advancing
clinical work in this field," stated Professor Wilson. "It is gratifying to
see the years of preclinical work that we undertook at UCL evolve into a
successful therapy for such a pervasive disease."

    About Periowave(TM) and Photodisinfection

    Periowave(TM) is a Photodisinfection system developed by Ondine that
utilizes low-intensity lasers and wavelength-specific, light-activated
photosensitive compounds to specifically target and destroy microbial
pathogens and reduce the symptoms of disease. The compounds are topically
applied and lasers of appropriate wavelength and intensity are used to
disinfect the treatment site. The Photodynamic Disinfection technologies were
developed by Professor Michael Wilson and colleagues at the Eastman Dental
Institute, University College London, and licensed to Ondine by UCL Biomedica
plc, University College London. Additional information about Periowave(TM) is
available at www.periowave.com.

    About Ondine Biopharma Corporation

    Ondine is developing non-antibiotic therapies for the treatment of a
broad spectrum of bacterial, fungal and viral infections. The Company is
focused on creating and commercializing leading edge products utilizing its
patented light-activated technology. Photodisinfection provides broad-spectrum
antimicrobial efficacy without encouraging the formation and spread of
antibiotic resistance. The Company is headquartered in Vancouver, British
Columbia, Canada, with a research laboratory in Bothell, Washington, USA, and
an international office in St. Michael, Barbados. For additional information,
please visit the Company's website at: www.ondinebiopharma.com

    Forward-Looking Statements:

    Certain statements contained in this release containing words like
"believe", "intend", "may", "expect" and other similar expressions, are
forward-looking statements that involve a number of risks and uncertainties.
Factors that could cause actual results to differ materially from those
projected in the Company's forward-looking statements include the following:
market acceptance of our technologies and products; our ability to obtain
financing; our financial and technical resources relative to those of our
competitors; our ability to keep up with rapid technological change;
government regulation of our technologies; our ability to enforce our
intellectual property rights and protect our proprietary technologies; the
ability to obtain and develop partnership opportunities; the timing of
commercial product launches; the ability to achieve key technical milestones
in key products and other risk factors identified from time to time in the
Company's filings.

    The TSX Exchange has not reviewed and does not accept responsibility for
    the adequacy or accuracy of this release




For further information:

For further information: Carolyn Cross, President and Chief Executive
Officer, Ondine Biopharma Corporation, (604) 669-0555,
ccross@ondinebiopharma.com; Christina Bessant, Investor Relations, The Equicom
Group Inc., (416) 815-0700 ext. 269, cbessant@equicomgroup.com; Irma
Gomez-Dib, US Media Relations, FD, (212) 850-5600, Irma.gomez.dib@fd.com;
Nominated Adviser, Neil Johnson, Ryan Gaffney, Canaccord Adams Ltd, +44(0)20
7050 6500

Organization Profile

ONDINE BIOPHARMA CORPORATION

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890